Onesource Specialty Pharma Share Price Target 2027, 2028 and 2030: Long Term Analyst Forecast

CMP Rs 1640. FY26 EPS Rs N/A; approximately 12% annual growth. Target 2027: Rs 1,945 (+19%). Target 2028: Rs 2,530. Target 2030: Rs 4,280 (+161%).

Onesource Specialty Pharma at Rs 1,640 is positioned as India’s only dedicated CDMO for GLP-1 class drug-device combinations, specifically manufacturing injectable pens for semaglutide-type weight-loss drugs. In the global obesity treatment wave, CDMO capacity for GLP-1 injectables is among the most scarce manufacturing capabilities globally. The Onesource share price target of Rs 1,945 for 2027, rising to Rs 4,280 by 2030, reflects 30 percent annual earnings growth from a still loss-making base.

The Onesource Specialty Pharma share price target of Rs 1,945 for 2027, rising to Rs 4,280 by 2030, reflects approximately 12% annual earnings growth with a forward multiple consistent with CDMO (GLP-1 Injectables) peers. This article covers the Onesource Specialty Pharma share price target 2027, 2028, and 2030 based on FY26 financials and analyst estimates as of August 2026.

Click Here – Get Free Investment Predictions

Onesource Specialty Pharma Company Overview

What most investors miss: Carved out of the Strides and Steriscience ecosystem, Onesource is positioned as a picks-and-shovels GLP-1 play, a CDMO manufacturer of injectable pens and drug-device combinations for semaglutide-class weight-loss drugs. This is a scarce, high-margin capability riding the obesity drug boom. The company is still loss-making, and the 2027 target is anchored to the street consensus, not EPS multiples. The scale-up to profitability through FY28 to FY29 is the critical milestone.

Since the company is still loss-making, we’ve anchored to the ₹1,947 street target and rolled it forward assuming approximately30% underlying growth. . The share price targets of Rs 1,945 for 2027, Rs 2,530 for 2028, and Rs 4,280 for 2030 are derived from this earnings trajectory and peer multiples.

Why Is the Onesource Specialty Pharma Share Price Target Set at Rs 1,945 for 2027

GLP-1 Injectable Pen CDMO Capacity Is Among the Scarcest in Global Pharma

This is the foundational driver of the Onesource Specialty Pharma share price target of Rs 1,945 for 2027 and Rs 4,280 by 2030. Since the company is still loss-making, we’ve anchored to the ₹1,947 street target and rolled it forward assuming approximately30% underlying growth. The market will progressively price this as quarterly data confirms the trajectory.

Semaglutide Class Drug Demand Creates Multi-Year Manufacturing Revenue Backlog

Investors analysing the Onesource Specialty Pharma share price target should track this dimension quarterly, as it provides the clearest signal of whether the compounding thesis is on track. Evidence of sustained improvement in this area is the primary re-rating catalyst for the Onesource Specialty Pharma share price target 2028 of Rs 2115.

Drug-Device Combination Manufacturing Expertise Has a Very High Entry Barrier

This structural factor is often underweighted in standard Onesource Specialty Pharma share price target analyses, which focus on trailing earnings multiples rather than the competitive positioning embedded in the long-term franchise value. Its persistence through economic cycles is what differentiates the Onesource Specialty Pharma share price target 2030 case from a short-term trading call.

Strides and Steriscience Ecosystem Provides Regulatory and Technical Backbone

For the Onesource Specialty Pharma share price target of Rs 4,280 to materialise by 2030, this factor needs to remain intact and compound over 4 years. Quarterly updates on this metric provide the earliest warning signal of any deviation from the Onesource Specialty Pharma share price target base case assumptions.

Path to Profitability by FY28 Is the Key Milestone for Target Achievement

As India’s economy compounds through 2027 to 2030, this factor provides an additional secular tailwind that is layered on top of the Onesource Specialty Pharma-specific earnings growth already embedded in the Rs 1,945 target for 2027 and the Rs 4,280 target for 2030.

Onesource Specialty Pharma Share Price Targets 2027, 2028 and 2030

Onesource Specialty Pharma Share Price Target 2027: Rs 1,945

The Onesource Specialty Pharma share price target 2027 is Rs 1,945, representing approximately 19 percent upside from CMP Rs 1640. Since the company is still loss-making, we’ve anchored to the ₹1,947 street target and rolled it forward assuming approximately30% underlying growth.. By 2027, the key catalyst for achieving this level is validation of the earnings trajectory through 2 consecutive quarters of on-target performance.

Onesource Specialty Pharma Share Price Target 2028: Rs 2,530

The Onesource Specialty Pharma share price target 2028 is Rs 2,530, implying approximately 54 percent upside from CMP. By 2028, Onesource Specialty Pharma should have demonstrated through a full earnings cycle that the approximately 12% growth assumption is sustainable, supporting a re-rating toward the Onesource Specialty Pharma share price target 2028 level at a forward multiple consistent with sector peers.

Onesource Specialty Pharma Share Price Target 2030: Rs 4,280

The Onesource Specialty Pharma share price target 2030 is Rs 4,280, implying approximately 161 percent upside from CMP and a 4-year CAGR of approximately 27% from current levels. By 2030, Onesource Specialty Pharma should be a mature, well-understood franchise with a track record of consistent compounding that justifies the target multiple.

Bull Case and Bear Case for the Onesource Specialty Pharma Share Price Target 2030

Bull Case: Rs 5,478

The bull case Onesource Specialty Pharma share price target of Rs 5,478 by 2030: Rs 5,500 by 2030, if GLP-1 demand exceeds global supply and Onesource secures multi-year contracts with multiple top-tier pharma companies, driving 40 percent annual revenue growth and early profitability by FY27.

Bear Case: Rs 3,253

The bear case Onesource Specialty Pharma share price target of Rs 3,253 by 2030: Rs 2,800 by 2030, if GLP-1 drug demand growth is slower than expected, global pharma companies prefer in-house manufacturing, and Onesource’s losses persist beyond FY28, requiring dilutive equity raises.

Key Risks to the Onesource Specialty Pharma Share Price Target

USFDA Inspection and Compliance Risk

Any USFDA warning letter or import alert on Onesource Specialty Pharma’s manufacturing facilities would delay product launches and revenue recognition, directly reducing the earnings trajectory behind the Onesource Specialty Pharma share price target. USFDA inspection history is the most important risk indicator to track.

Currency Risk on Export Revenue

Onesource Specialty Pharma’s international revenue is primarily in US dollars and euros. Any significant INR appreciation against these currencies would reduce the INR value of reported revenues and EPS, compressing the Onesource Specialty Pharma share price target earnings assumptions.

Pricing Pressure in Regulated Generic Markets

In the US and EU generic markets, pricing erosion from competition intensifies as multiple players receive approvals for the same molecule. Any acceleration in generic pricing erosion in Onesource Specialty Pharma’s key export products would compress the Onesource Specialty Pharma share price target revenue base.

Clinical Trial and Pipeline Risk

Any setback in Onesource Specialty Pharma’s clinical trial results or regulatory approvals for pipeline products would delay the revenue ramp from specialty or novel products embedded in the Onesource Specialty Pharma share price target 2028 and 2030 assumptions.

How to Invest in Onesource Specialty Pharma

Use the Univest Screener to track Onesource Specialty Pharma’s key financial metrics including EPS growth, margin trends, and analyst upgrades or downgrades in real time. To purchase shares, open a demat account with any SEBI-registered broker and search for NSE ticker ONESOURCE. Review the quarterly earnings data, the sector-specific risk indicators outlined in this article, and build a position size proportionate to your risk tolerance and investment horizon. Monitor each quarter for the key variables most likely to move the Onesource Specialty Pharma share price target. Consult a SEBI-registered financial advisor before making any investment decision.

Use the Univest Screener to Track This Stock Live

Conclusion

The Onesource Specialty Pharma share price target of Rs 1,945 for 2027, Rs 2,530 for 2028, and Rs 4,280 for 2030 reflects approximately 12% annual earnings compounding and a forward multiple consistent with CDMO (GLP-1 Injectables) peers. The key drivers and risks are outlined above. Carved out of the Strides and Steriscience ecosystem, Onesource is positioned as a picks-and-shovels GLP-1 play, a CDMO manufacturer of injectable pen. For investors with a 3 to 4 year horizon and a tolerance for CDMO (GLP-1 Injectables)-specific risk, the current CMP of Rs 1640 offers a starting point for building a position aligned to the Onesource Specialty Pharma share price target 2030 thesis. Always verify data at NSE and BSE before investing.

Download the Univest iOS App or Univest Android App to track Onesource Specialty Pharma share price live and get daily stock recommendations.

Frequently Asked Questions on Onesource Specialty Pharma Share Price Target 2027 2028 and 2030

What is the Onesource Specialty Pharma share price target for 2027?

Ans. The Onesource Specialty Pharma share price target for 2027 is Rs 1,945, representing approximately 19 percent upside from CMP Rs 1640 as of August 2026. Please verify all data with the official NSE website before making any investment decision.

What is the Onesource Specialty Pharma share price target for 2030?

Ans. The Onesource Specialty Pharma share price target for 2030 is Rs 4,280, implying approximately 161 percent upside from CMP Rs 1640. This is based on analyst estimates and is not a guaranteed return. Always verify current data at NSE India before investing.

Is Onesource Specialty Pharma a good long-term investment?

Ans. Onesource Specialty Pharma has a defined analyst consensus that projects earnings compounding through FY31 based on sector-specific growth drivers outlined in this article. Whether it suits your portfolio depends on your risk appetite, investment horizon, and existing allocation. Consult a SEBI-registered financial advisor for personalised guidance.

What do most investors miss about Onesource Specialty Pharma?

Ans. Carved out of the Strides/Steriscience ecosystem, it is positioned as a ‘picks-and-shovels’ GLP-1 play – a contract maker of injectable pens/drug-device combinations for semaglutide-class weight-loss drugs as patents expire – which is why the market pays up despite a TTM loss; borrowings nearly doub

What is the bull case for the Onesource Specialty Pharma share price target 2030?

Ans. The bull case Onesource Specialty Pharma share price target for 2030 is Rs 5,478. This requires better-than-base-case execution on the key growth drivers specific to Onesource Specialty Pharma’s sector, as described in this article. These are analyst projections, not guaranteed returns.

What are the main risks to the Onesource Specialty Pharma share price target?

Ans. The key risks to the Onesource Specialty Pharma share price target include sector-specific headwinds such as credit cycles (for financial companies), regulatory changes, competitive pressure, and macroeconomic slowdown. Please review the risks section of this article for a full breakdown of the four most material risks.

What is Onesource Specialty Pharma’s 52-week high and low share price?

Ans. As of August 2026, Onesource Specialty Pharma’s 52-week high is approximately Rs 2,100 and the 52-week low is approximately Rs 1,200. The CMP of Rs 1640 sits between these levels. Always verify the latest 52-week data at NSE India or BSE before making any investment decision.

How can I buy Onesource Specialty Pharma shares?

Ans. You can buy Onesource Specialty Pharma shares through any SEBI-registered broker by searching for the NSE ticker ONESOURCE. Before investing, review the fundamentals outlined in this article and consult a SEBI-registered financial advisor for guidance aligned to your specific financial goals.